...I participated in the current Pagaclone study. I've picked up from sources in the study that Endo Pharmaceutical is having a summit next Tuesday at their headquarters to decide to kill the Pagaclone study or (1) continue the existing study allowing monitoring document to increase the dose in patients they believe would benefit; or (2) extend the study using higher dosages to see if that improves fluency (this additional phase of the test would only take 8 weeks and would potentially save the more than five years devoted to testing this drug); or (3) allow current users that feel they benefit significantly from the drug to continue under a "compassionate use" program; or (4) close the program and give up on the only drug that has helped a substantial number of stutters (like me)...I am wondering who is attending the summit. How much do these people know about stuttering? And how much do the experts on stuttering know about statistics and random control trials? I would love to be there, and see how good the debate is. But I can already guess the absurdity of the situation: it's about millions of dollars and people from different backgrounds being parachuted into this summit with very different agendas and very few lucid science brains.
Tuesday, August 24, 2010
Today is decision time on Pagoclone?
We already know that the Pagoclone trial have been stopped, but not apparently not completely. According to a reader, today is decision time. A reader writes